Analysts have been eager to weigh in on the Healthcare sector with new ratings on Emergent Biosolutions (EBS – Research Report), Syndax Pharmaceuticals (SNDX – Research Report) and Mersana Therapeutics (MRSN – Research Report).
Emergent Biosolutions (EBS)
In a report released yesterday, Jessica Fye from J.P. Morgan downgraded Emergent Biosolutions to Sell, with a price target of $9.00. The company’s shares closed last Thursday at $10.18.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
Currently, the analyst consensus on Emergent Biosolutions is a Hold with an average price target of $15.00.
See today’s best-performing stocks on TipRanks >>
Syndax Pharmaceuticals (SNDX)
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Syndax Pharmaceuticals yesterday and set a price target of $34.00. The company’s shares closed last Thursday at $20.66.
According to TipRanks.com, Rama is a 2-star analyst with an average return of
Currently, the analyst consensus on Syndax Pharmaceuticals is a Strong Buy with an average price target of $34.00.
Mersana Therapeutics (MRSN)
Mersana Therapeutics received a Buy rating and a $10.00 price target from J.P. Morgan analyst Brian Cheng yesterday. The company’s shares closed last Thursday at $4.00.
According to TipRanks.com, Cheng ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Mersana Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EBS:
- Emergent says over-the-counter Narcan will be available by late summer
- U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
- Emergent BioSolutions rises 17.5%
- FDA approves Emergent’s Narcan for over-the-counter use
- Emergent BioSolutions falls -10.3%
